Immunological predictors in children with hypoxic-ischemic encephalopathy

1. Karkashadze GA, Anikin AV, Zimina EP, Davydova IV, Karimova KhM [i dr.]. Recent Information on the Pathogenesis and Treatment of Hypoxic-Ischemic Brain Lesions in Newborns. Pediatricheskaya farmakologiya. 2016; 13 (5): 452–467. (In Russ.)

2. Boskabadi H, Moradi A, Zakerihamidi M. Interleukins in diagnosis of perinatal asphyxia: A systematic review. Int J Reprod Biomed (Yazd). 2018; 17 (5): 303–314. doi: 10.18502/ijrm.v17i5.4598

3. Jiang LJ, Xu ZX, Wu MF, Dong GQ, Zhang LL [et al.]. Resatorvid protects against hypoxic-ischemic brain damage in neonatal rats. Neural Regen Res. 2020; 15 (7): 1316–1325. doi: 10.4103/1673-5374.272615

4. Grasselli C. Toll-like receptor 4 modulation influences human neural stem cell proliferation and differentiation / C Grasselli, D Ferrari, C Zalfa, M Soncini, G Mazzoccoli, FA Facchini, L Marongiu, F Granucci, M Copetti, AL Vescovi, F Peri, L De Filippis. Cell Death Dis. 2018. Vol. 15. № 9 (3). P. 280.

5. Federal’noe rukovodstvo po detskoy nevrologii / Pod redaktsiey professora Guzevoy VI. M.: OOO «MK», 2016. 656 s. (In Russ.)

6. Debillon T, Bednarek N, Ego A. LyTONEPAL: longterm outcome of neonatal hypoxic encephalopathy in the era of neuroprotective treatment with hypothermia: a French population-based cohort. BMC Pediatr. 2018; 18: 255. https://doi.org/10.1186/s12887-018-1232-6

7. Barycheva LYu, Idrisova AS, Kuzmina ES, Agranovich OV. Clinical significance of proinflammatory interleukins in newborns with hypoxic-ischemic CNS damage. Meditsinskiy vestnik Severnogo Kavkaza — Medical News of North Caucasus. 2021; 16 (3): 310–312. (In Russ.)